Table 4 Cox univariate analysis showing variables associated with treatment failure during daptomycin-based antimicrobial therapy
Variable | n (%) | unadjusted HR (95 % CI) | p-value |
|---|---|---|---|
Age (per 10 years) | NA | 1.89 (1.03–3.47) | 0.041 |
Male sex | 23 (59) | 1.48 (0.25–1.48) | 0.245 |
Obesity | 12 (31) | 1.06 (0.93–1.06) | 0.932 |
ASA score | NA | 1.11 (0.79–1.11) | 0.787 |
Smoking | 13 (33) | 0.91 (0.23–3.65) | 0.896 |
Implant associated BJI | 33 (85) | 27.8 (0.02–40422.69) | 0.371 |
Chronic BJI | 5 (13) | 1.15 (0.14–9.22) | 0.894 |
Fistula | 14 (36) | 2.94 (0.60–14.43) | 0.185 |
Relapsing BJI | 15 (63) | 5.50 (0.69–44.02) | 0.108 |
S. aureus | 11 (28) | 0.59 (0.12–2.89) | 0.517 |
No or non-optimal surgery | 15 (38) | 3.63 (0.91–14.73) | 0.068 |
Previous treatment with glycopeptides | 34 (87) | 25.47 (0.01–142518.48) | 0.462 |
Glycopeptide-resistant isolate | 20 (51) | 2.965 (0.70–12.58) | 0.141 |
Daptomycin ≤ 8 mg/kg/d | 26 (67) | 0.676 (0.18–2.55) | 0.563 |
Daptomycin discontinuation for SAE | 6 (15) | 4.844 (1.17–20.05) | 0.029 |